Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

Author: j3ff1

Home Articles Posted by j3ff1 (Page 4)
126 posts, 0 comments

3/10/22 – Proactive Investors: RespireRx Pharmaceuticals is developing innovative and revolutionary treatments to combat neuronal signaling disorders

March 10, 2022j3ff1
Read More

3/7/22 – Proactive Investors: RespireRx Pharmaceuticals CEO announces internal restructuring, plans further clinical trials in 2022

March 10, 2022j3ff1
Read More

3/7/2022 – Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward

March 7, 2022j3ff1
Read More

1/24/2022 – RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain

January 24, 2022j3ff1
Read More

12/14/2021 – RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase

December 14, 2021j3ff1
Read More

12/6/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81

December 6, 2021j3ff1
Read More

11/30/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81

November 30, 2021j3ff1
Read More

11/29/2021 – RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury

November 29, 2021j3ff1
Read More

11/22/2021 – RespireRx Pharmaceuticals Inc. Announces CEO’s OTC Venture Market Podcast

November 22, 2021j3ff1
Read More

WATCH: RespireRx CFO Jeff Margolis Discusses Clinical Pipeline with Proactive Investors

November 4, 2021j3ff1

RespireRx Pharmaceuticals (OTCQB:RSPI) CFO Jeff Margolis tells Proactive the Glen Rock, New Jersey-based group is advancing its slew of therapeutics throughout the clinical pipeline including a synthetic form of cannabinoid called dronabinol. Margolis says it aims to move to a Phase 3 clinical study to treat obstructive sleep apnea (OSA) with dronabinol. Meanwhile, Margolis says…

Read More

Posts pagination

< 1 2 3 4 5 6 7 … 13 >

RespireRx Organization Structure

  • RespireRx Organization Structure
  • Arnold S. Lippa, PhD
    • Richard Purcell
    • David Dickason
    • James Cook
    • Jeffrey M. Witkin
    • Rok Cerne
  • Jeff Margolis
©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.